Anja Lux

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2143333/publications.pdf

Version: 2024-02-01

34 papers	2,199 citations	361413 20 h-index	395702 33 g-index
37 all docs	37 docs citations	37 times ranked	3562 citing authors

#	Article	IF	Citations
1	Bâ€cell modulation with antiâ€CD79b antibodies ameliorates experimental autoimmune encephalitis in mice. European Journal of Immunology, 2022, 52, 656-668.	2.9	0
2	Targeting B cells in the pre-phase of systemic autoimmunity globally interferes with autoimmune pathology. IScience, 2021, 24, 103076.	4.1	6
3	Expression Profiling and Glycan Engineering of IgG Subclass 1â€“4 in Nicotiana benthamiana. Frontiers in Bioengineering and Biotechnology, 2020, 8, 825.	4.1	12
4	Fc-engineering significantly improves the recruitment of immune effector cells by anti-ICAM-1 antibody MSH-TP15 for myeloma therapy. Haematologica, 2020, 106, haematol.2020.251371.	3.5	11
5	Impact of Plasma Membrane Domains on IgG Fc Receptor Function. Frontiers in Immunology, 2020, 11, 1320.	4.8	18
6	Complement-Dependent Activity of CD20-Specific IgG Correlates With Bivalent Antigen Binding and C1q Binding Strength. Frontiers in Immunology, 2020, 11, 609941.	4.8	13
7	Human FcÎ³-receptor IIb modulates pathogen-specific versus self-reactive antibody responses in lyme arthritis. ELife, 2020, 9, .	6.0	8
8	Fra1 Controls Rheumatoid Factor Autoantibody Production by Bone Marrow Plasma Cells and the Development of Autoimmune Bone Loss. Journal of Bone and Mineral Research, 2019, 34, 1352-1365.	2.8	10
9	The Immunological Organ Environment Dictates the Molecular and Cellular Pathways of Cytotoxic Antibody Activity. Cell Reports, 2019, 29, 3033-3046.e4.	6.4	18
10	Minimal B Cell Extrinsic IgG Glycan Modifications of Pro- and Anti-Inflammatory IgG Preparations in vivo. Frontiers in Immunology, 2019, 10, 3024.	4.8	23
11	Detection of Experimental and Clinical Immune Complexes by Measuring SHIP-1 Recruitment to the Inhibitory FcÎ³RIIB. Journal of Immunology, 2018, 200, 1937-1950.	0.8	8
12	Dissecting FcÎ³R Regulation through a Multivalent Binding Model. Cell Systems, 2018, 7, 41-48.e5.	6.2	28
13	IgG Fc domains that bind C1q but not effector FcÎ³ receptors delineate the importance of complement-mediated effector functions. Nature Immunology, 2017, 18, 889-898.	14.5	122
14	IgG subclass and vaccination stimulus determine changes in antigen specific antibody glycosylation in mice. European Journal of Immunology, 2017, 47, 2070-2079.	2.9	41
15	Regulation of autoantibody activity by the IL-23â€“TH17 axis determines the onset of autoimmune disease. Nature Immunology, 2017, 18, 104-113.	14.5	274
16	A Monosaccharide Residue Is Sufficient to Maintain Mouse and Human IgG Subclass Activity and Directs IgG Effector Functions to Cellular Fc Receptors. Cell Reports, 2015, 13, 2376-2385.	6.4	86
17	Pathways Responsible for Human Autoantibody and Therapeutic Intravenous IgG Activity in Humanized Mice. Cell Reports, 2015, 13, 610-620.	6.4	38
18	FcÎ³R dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities. Trends in Immunology, 2015, 36, 325-336.	6.8	157

#	Article	IF	Citations
19	Suppression of FcÎ³-Receptor-Mediated Antibody Effector Function during Persistent Viral Infection. Immunity, 2015, 42, 379-390.	14.3	58
20	No Need for Constant Help: Human IgG2 Antibodies Have an Autonomous Agonistic Activity for Immunotherapy of Cancer. Cancer Cell, 2015, 27, 10-11.	16.8	7
21	Glycosylation of immunoglobulin G determines osteoclast differentiation and bone loss. Nature Communications, 2015, 6, 6651.	12.8	212
22	Reply to â€" IVIG pluripotency and the concept of Fc-sialylation: challenges to the scientist. Nature Reviews Immunology, 2014, 14, 349-349.	22.7	27
23	Boneâ€•and Cartilageâ€Protective Effects of a Monoclonal Antibody Against Colonyâ€Stimulating Factor 1 Receptor in Experimental Arthritis. Arthritis and Rheumatology, 2014, 66, 2989-3000.	5.6	58
24	How Immunoglobulin G Antibodies Kill Target Cells. Advances in Immunology, 2014, 124, 67-94.	2.2	37
25	Targeting B cells and autoantibodies in the therapy of autoimmune diseases. Seminars in Immunopathology, 2014, 36, 289-299.	6.1	13
26	A Humanized Mouse Identifies the Bone Marrow as a Niche with Low Therapeutic IgG Activity. Cell Reports, 2014, 7, 236-248.	6.4	47
27	Impact of Immune Complex Size and Glycosylation on IgG Binding to Human FcÎ³Rs. Journal of Immunology, 2013, 190, 4315-4323.	0.8	234
28	Inflammatory monocytes and FcÎ³ receptor IV on osteoclasts are critical for bone destruction during inflammatory arthritis in mice. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 10729-10734.	7.1	153
29	FcÎ³RIIB: a modulator of cell activation and humoral tolerance. Expert Review of Clinical Immunology, 2012, 8, 243-254.	3.0	26
30	Monocyte Subsets Responsible for Immunoglobulin G-Dependent Effector Functions InÂVivo. Immunity, 2011, 35, 932-944.	14.3	127
31	FcÎ³ receptor IIB (FcÎ³RIIB) maintains humoral tolerance in the human immune system in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 18772-18777.	7.1	74
32	The role of FcÎ³ receptors in murine autoimmune thrombocytopenia. Annals of Hematology, 2010, 89, 25-30.	1.8	21
33	FcÎ³RIV deletion reveals its central role for IgG2a and IgG2b activity in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 19396-19401.	7.1	168
34	The Kaposi's Sarcoma-associated Herpesvirus-encoded vIRF-3 Inhibits Cellular IRF-5. Journal of Biological Chemistry, 2009, 284, 8525-8538.	3.4	64